Explore 3 Stock Ideas & Industry Insights Download Free Report

Palisade Bio Inc

Company price
0.8399 USD -0.09 ( 9.24%)
Last update at 2026-11-20T21:00:00Z
VOLUME
3180943
Market Cap
351.16M
P/E
3.15

Momentum Score

…

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.84
Low
0.96
High
52 Week Price Range
0.57
Low
2.86
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Palisade Bio Inc (NASDAQ: PALI) is a clinical-stage biopharmaceutical company developing therapeutic candidates and advancing programs through clinical development toward potential regulatory approval. Long-term growth drivers may include clinical trial progress, favorable regulatory outcomes, strategic partnerships and eventual commercialization, and investors may find the company attractive for potential upside if its programs address unmet medical needs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.93
Dividend Yield
-
Revenue TTM
0.50M
Revenue Per Share
0.00
Gross Profit TTM
0.50M
Debt / Equity
0.00
ROE
-51.37%
Net Debt
-133.31M
ROCE
-12.93%
Diluted EPS TTM
0.64

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -16.78M -14.44M -12.30M -14.26M -26.62M
Net income -16.78M -14.44M -12.30M -12.80M -27.27M
Selling general administrative 7.86M 5.80M 6.20M 8.76M 9.31M
Selling and marketing expenses - - 0.00M - -
Gross profit -0.00M -0.00M 0.25M - -
Reconciled depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Ebit -16.77M -14.43M -12.29M -15.72M -41.85M
Ebitda -16.77M -14.42M -12.28M -15.15M -44.28M
Depreciation and amortization 0.00M 0.00M 0.00M 0.57M -2.43M
Operating income -18.06M -14.86M -13.07M -15.72M -41.85M
Other operating expenses 18.06M 14.86M 13.32M 15.31M 41.85M
Interest expense 0.01M 0.01M 0.01M 0.01M 2.40M
Net interest income -0.01M -0.01M -0.01M -0.01M -3.08M
Income tax expense - - 0.02M -1.46M 0.66M
Total revenue 0.00M 0.00M 0.25M 0.00M 0.00M
Total operating expenses 18.06M 14.86M 13.32M 15.31M 41.85M
Cost of revenue 0.00M 0.00M 0.00M - -
Total other income expense net 1.27M 0.42M 0.77M 1.46M 15.24M
Net income from continuing ops -16.78M -14.44M -12.30M -14.26M -26.62M
Net income applicable to common shares - - - -14.55M -26.62M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 134.34M 10.88M 14.05M 15.76M 12.51M
Other current assets 0.57M 0.65M 0.64M 2.35M 1.88M
Total liab 4.96M 3.39M 2.74M 3.28M 5.15M
Total stockholder equity 129.38M 7.49M 11.31M 12.48M 7.37M
Other current liab 3.80M 1.85M 1.61M 0.99M 0.78M
Common stock 1.59M 0.03M 0.09M 0.03M 0.14M
Capital stock 1.60M 0.03M 0.10M 0.03M 0.14M
Retained earnings -152.72M -135.94M -121.51M -109.19M -94.64M
Other liab - - - - 2.65M
Other assets - - - - 0.03M
Cash 133.38M 9.82M 12.43M 12.38M 10.49M
Total current liabilities 4.64M 3.24M 2.59M 3.01M 2.50M
Net debt -133.31M -9.65M -12.06M -11.98M -10.30M
Short term debt 0.07M 0.17M 0.28M 0.19M 0.20M
Short long term debt 0.07M 0.08M 0.16M 0.09M 0.09M
Short long term debt total 0.07M 0.17M 0.37M 0.40M 0.20M
Other stockholder equity 280.51M 143.41M 132.72M 121.64M 101.86M
Property plant equipment - - - - 0.11M
Total current assets 134.22M 10.49M 13.22M 14.73M 12.37M
Net tangible assets - - - - 7.36M
Net receivables 0.26M 0.02M 0.15M 1.44M 0.15M
Inventory - 0.01M - -1.44M -0.15M
Accounts payable 0.77M 1.21M 0.70M 1.83M 1.52M
Accumulated other comprehensive income - - 0.00M - -
Non currrent assets other 0.07M 0.27M 0.60M 0.72M 0.03M
Non current assets total 0.12M 0.36M 0.84M 1.03M 0.14M
Capital lease obligations 0.00M 0.09M 0.21M 0.32M 0.11M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M -0.00M -0.01M -0.05M
Change to liabilities - - - - -2.40M
Total cashflows from investing activities - - -0.00M - -0.05M
Net borrowings -0.32M -0.43M -0.39M - -0.18M
Total cash from financing activities 134.44M 9.58M 11.19M 15.26M 24.61M
Change to operating activities - - - - -2.44M
Net income -16.78M -14.44M -12.30M -14.26M -26.62M
Change in cash 123.59M -2.61M 0.05M 1.89M 9.78M
Begin period cash flow 9.85M 12.46M 12.41M 10.52M 0.74M
End period cash flow 133.44M 9.85M 12.46M 12.41M 10.52M
Total cash from operating activities -10.85M -12.19M -11.13M -13.36M -14.77M
Issuance of capital stock 128.22M 8.44M 9.42M 14.40M 25.11M
Depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Change to account receivables - - - - 0.08M
Sale purchase of stock 0.02M 0.01M 0.02M - -
Other cashflows from financing activities -0.49M 1.57M 2.16M 1.65M 20.83M
Change to netincome - - - - 14.26M
Capital expenditures 0.00M 0.00M 0.00M 0.01M 0.00M
Change in working capital 1.64M 1.39M 0.40M 1.25M -4.76M
Stock based compensation 3.96M 0.65M 0.62M 1.03M 1.89M
Other non cash items 0.34M 0.20M 0.14M -1.39M 34.77M
Free cash flow -10.85M -12.19M -11.14M -13.37M -14.77M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PALI
Palisade Bio Inc
-0.09
9.24%
0.84 3.15 - 702.31 2.93 448.71 0.57
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Palisade Bio Inc

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

4600 South Syracuse Street, Denver, CO, United States, 80237

858 704 4900

14

Name Title Year Born
Mr. J. D. Finley Interim CEO & CFO 1957
Ms. Sharon McBrayer Director of Operations NA
Mr. Robert C. McRae Sr. VP of Operations & Strategic Devel. NA
Dr. Herbert B. Slade FAAAAI, M.D. Chief Medical Officer NA
Mr. Ryker Willie VP of Fin. & Corp. Controller NA
Mr. J. D. Finley CEO, CFO & Director 1958
Dr. Mitchell Lawrence Jones M.D., Ph.D. COO & Chief Medical Officer 1978
Mr. Ryker Willie Senior VP of Finance & Corporate Controller NA
Dr. Mitchell Lawrence Jones M.D., Ph.D. President & Chief Medical Officer 1977
Mr. Ramesh C. Donthamsetty Head of Corporate Development & Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…